Certara, Inc. (NASDAQ:CERT) Shares Bought by Geneva Capital Management LLC

Geneva Capital Management LLC raised its holdings in Certara, Inc. (NASDAQ:CERT) by 0.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,510,209 shares of the company’s stock after purchasing an additional 37,392 shares during the period. Geneva Capital Management LLC’s holdings in Certara were worth $64,525,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Blue Trust Inc. purchased a new position in shares of Certara during the 2nd quarter valued at approximately $26,000. Innealta Capital LLC purchased a new position in Certara during the second quarter valued at $36,000. Intech Investment Management LLC acquired a new stake in shares of Certara in the second quarter valued at about $152,000. Algert Global LLC purchased a new stake in shares of Certara during the second quarter worth about $156,000. Finally, MQS Management LLC acquired a new position in shares of Certara during the 2nd quarter worth about $162,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CERT has been the topic of several research analyst reports. Robert W. Baird lowered their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a research note on Friday, September 27th. Finally, Barclays reduced their price objective on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Certara presently has a consensus rating of “Hold” and an average price target of $15.92.

Insiders Place Their Bets

In other news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Certara news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the sale, the insider now owns 99,704 shares in the company, valued at $1,125,658.16. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is owned by insiders.

Certara Stock Performance

NASDAQ:CERT opened at $10.60 on Wednesday. Certara, Inc. has a one year low of $9.99 and a one year high of $19.87. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a 50 day moving average price of $10.97 and a 200 day moving average price of $13.58.

Certara (NASDAQ:CERT) last issued its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same period last year, the company earned $0.06 EPS. On average, analysts forecast that Certara, Inc. will post 0.27 EPS for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.